Published online Nov 27, 2023. doi: 10.4240/wjgs.v15.i11.2413
Peer-review started: June 26, 2023
First decision: July 17, 2023
Revised: July 24, 2023
Accepted: August 15, 2023
Article in press: August 15, 2023
Published online: November 27, 2023
Gallbladder cancer (GC) is one of the most deadly malignancies worldwide, with a high incidence of peritoneal meta
The primary research question was: Is CRS combined with HIPEC efficient and safe for managing GC? The key issues for resolution are the benefits and risks of this combined approach, including its effect on survival rates and postoperative complications compared with CRS. Addressing these questions is paramount to providing evidence-based guidance for clinicians for GC management; it could also potentially revolutionize the treatment paradigm and improve survival rates and quality of life for these patients. Moreover, it opens avenues for further research to optimize CRS-HIPEC protocols and identify patient subgroups that could benefit the most from this approach.
The main objective of this study was to evaluate the efficacy and safety of CRS combined with HIPEC for managing GC. We aimed to comprehensively understand the impact of CRS-HIPEC on survival rates and postoperative complications, which is crucial for future research as it informs clinical decision-making and establishes a foundation for refining trea
This study employed a retrospective analysis of the medical records of patients with GC treated with CRS-HIPEC. This method allows for a thorough examination of patient outcomes and treatment complications. Additionally, this study includes a comparative analysis of patients receiving CRS, highlighting the novel aspects of the CRS-HIPEC approach.
CRS-HIPEC significantly improved the survival rates of patients with GC. This study also highlighted an increased risk of certain postoperative complications. These results contribute to the field by providing empirical evidence for the efficacy and safety of CRS-HIPEC.
CRS-HIPEC significantly improves survival rates but with certain risks. Furthermore, the results of this study underscore the need for personalized patient selection to maximize benefits and minimize complications.
Future research should focus on optimizing CRS-HIPEC protocols and developing criteria for patient selection, which would enhance the benefits of this approach and mitigate the potential risks. Prospective, randomized controlled trials are also needed to corroborate these findings.